Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628640 · ClinicalTrials.gov registry record · Phase 1
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01628640: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01628640 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01628640, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of the body and do not respond to treatment. The study virus has a gene inserted into it which will allow production of interferon beta, which is a substance that will restrict the spread of the virus to tumor cells and not healthy cells. It will also have some independent anti-cancer activity. Although the primary goal of this study is to evaluate the safety of delivery of this viral agent to people, patients may benefit clinically by having shrinkage or stabilization of their tumor or reduction in their cancer related symptoms (e.g., pain). Funding Source - FDA OOPD.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-08-03 |
| Est. Completion | 2019-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01628640
The ClinicalTrials.gov registry entry for NCT01628640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01628640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01628640 about?
NCT01628640 is a clinical study titled "Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors". This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of the body and do not respond to treatment. The study virus has a gene i...
What is the current status of trial NCT01628640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-08-03. Estimated completion is 2019-04-19.
What interventions are being tested in trial NCT01628640?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT01628640?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.